biotech

Handshake

Anavex Soars on Biogen Agreement

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) soared on Wednesday following a material transfer agreement with Biogen Inc. (NASDAQ: BIIB). As for the terms of this agreement, Biogen will ...
Read Full Story »
automatic inspection machine

Red-Hot Biotechs Highlight Jefferies Top Stocks to Buy This Week

With one presidential debate out of the way, and more right around the corner, one thing is for sure: at one point pharmaceutical costs and pricing may come up, and ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
analysis

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

Monday is kicking off a very important week in the markets, with earnings season on the horizon and the first presidential debate later in the evening. Biotech and pharmaceutical companies ...
Read Full Story »
money

How Much Will Consumers Save on New Humira Biosimilar?

Some interesting news that hit late last week may have been much larger news had not been going into the weekend. In a time when government wrangling about drug prices ...
Read Full Story »
graph

6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside

The world of biotech and pharmaceuticals has entered into a strange period. The presidential elections have many companies under fire over price control or price gouging issues. And valuations previously ...
Read Full Story »
thumbs up and down

Could Puma Biotech Double After This FDA Approval?

Puma Biotechnology Inc. (NYSE: PBYI) posted strong gains over the course of this past week, which began with some positive news from the U.S. Food and Drug Administration (FDA) and ...
Read Full Story »
upside

Why Key Analyst Sees Puma Biotech Practically Doubling

Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now ...
Read Full Story »
graph

Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential

Needless to say, the biotech world has had a very difficult year. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered ...
Read Full Story »
FDA_logo

How Sarepta Is Cashing In on Its FDA Homerun

Sarepta Therapeutics Inc. (NASDAQ: SRPT) watched its stock practically double in just the past week alone following a key FDA approval. There were a few factors that played into this ...
Read Full Story »
Female patient on gurney

Eleven Bio Finds Even More Pipeline Growth in M&A

Eleven Biotherapeutics Inc. (NASDAQ: EBIO) has been gaining ever attention as 2016 has gone on. The stock traded as low as $0.25 a share this spring and as high as $6 this ...
Read Full Story »
FDA_logo

Puma Biotech Rises on Key FDA Approval

Shares of Puma Biotechnology Inc. (NYSE: PBYI) had a strong gain in Tuesday’s session following some positive news from the U.S. Food and Drug Administration (FDA). The regulatory body announced that ...
Read Full Story »
FDA_logo

Sarepta Scores Big on Highly Contested FDA Approval

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is clearing another hurdle related to its Duchenne muscular dystrophy (DMD) treatment, eteplirsen. The stock practically doubled on Monday following the U.S. Food and Drug ...
Read Full Story »
Test tubes

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

We have talked in detail about how the political rhetoric has weighed upon the biotech industry. Toss in some scrutiny of pricing over a widely used product, and you have ...
Read Full Story »
burning cash

Is This the Ultimate Implosion of Novavax?

Novavax Inc. (NASDAQ: NVAX) was pummeled by shareholders on Friday after the company reported top-line results from its RSV F Vaccine trials. Essentially, the Resolve Phase 3 trial of RSV F ...
Read Full Story »